Echo, Strain, or Cardiac MRI? Choosing Cardiac Imaging in Survivorship Follow-Up

Echocardiography with strain as the default

For most survivors of anthracycline or HER2-targeted therapy, transthoracic echocardiography with ejection fraction and global longitudinal strain is the appropriate surveillance study. Strain falls before ejection fraction does, and a relative decline of more than fifteen percent from baseline identifies patients worth treating before symptoms or a measured drop in ejection fraction.

Consistency matters more than sophistication. Use the same laboratory and the same technique across studies so a change reflects the patient rather than the machine.

When cardiac MRI earns its cost

Reach for cardiac MRI when acoustic windows are poor, when echocardiographic findings conflict with the clinical picture, when myocarditis is suspected during immune checkpoint therapy, or when tissue characterisation such as fibrosis or infiltration would change what you do next. It also provides the most reproducible volumes when small serial changes are the deciding factor.

Cadence by exposure

Cadence follows cumulative exposure and baseline risk rather than a single rule. Higher cumulative anthracycline dose, combined chest radiation, pre-existing cardiovascular disease, and older age at treatment all shorten the interval. Document the chosen interval, the reason for it, and the clinician who owns ordering the next study.

Guideline sources move. Compare the current cardio-oncology surveillance recommendations against your local protocol at a set review date rather than assuming last year's schedule still holds.